SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-003941
Filing Date
2020-01-08
Accepted
2020-01-08 17:15:48
Documents
16
Period of Report
2020-01-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d864205d8k.htm   iXBRL 8-K 30076
2 EX-5.1 d864205dex51.htm EX-5.1 9751
3 EX-99.1 d864205dex991.htm EX-99.1 8159
7 GRAPHIC g864205g0107221831761.jpg GRAPHIC 3909
8 GRAPHIC g864205g0107222229665.jpg GRAPHIC 3429
  Complete submission text file 0001193125-20-003941.txt   189197

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA clvs-20200107.xsd EX-101.SCH 3087
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20200107_lab.xml EX-101.LAB 18138
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20200107_pre.xml EX-101.PRE 11419
9 EXTRACTED XBRL INSTANCE DOCUMENT d864205d8k_htm.xml XML 3356
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 20516411
SIC: 2834 Pharmaceutical Preparations